Impax Asset Management Group
TVTX icon

Impax Asset Management Group’s Travere Therapeutics TVTX Stock Holding History

Impax Asset Management Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17M Buy
300,000
+75,000
+33% +$3.33M 0.11% 126
2026
Q1 		$6.68M Hold
225,000
– – 0.05% 186
2025
Q4 		$8.6M Sell
225,000
-250,000
-53% -$8.13M 0.05% 160
2025
Q3 		$11.4M Hold
475,000
– – 0.07% 136
2025
Q2 		$7.03M Buy
475,000
+175,000
+58% +$2.9M 0.04% 176
2025
Q1 		$5.38M Hold
300,000
– – 0.03% 195
2024
Q4 		$5.23M Buy
+300,000
New +$5.31M 0.02% 217

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impax Asset Management Group's TVTX Position: Q2 2026 in Review

Impax Asset Management Group increased its Travere Therapeutics (TVTX) stake by 33% in Q2 2026, buying an estimated $3.33M and bringing the position to 300,000 shares worth $17M. The position accounts for 0.11% of the portfolio, ranked #126.

Impax Asset Management Group first reported a position in TVTX in Q4 2024 and has held it in 7 quarters since. 319 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Impax Asset Management Group held 300,000 shares of Travere Therapeutics worth $17M as of Q2 2026.
  • Impax Asset Management Group bought 75,000 Travere Therapeutics shares in Q2 2026, an estimated $3.33M.
  • Travere Therapeutics made up 0.11% of Impax Asset Management Group's portfolio in Q2 2026, its #126 holding.
  • Impax Asset Management Group first reported a position in Travere Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 319 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Impax Asset Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.